Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Phase 2

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

Interventions: Drug: OBP-301
Drug: Pembrolizumab

First Posted Date: 2020-12-28

Last Posted Date: 2023-01-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 1

Registration Number: NCT04685499

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Evaluation of PSMA Antagonist Produced by Two Different Methods

Phase 1

Completed

Conditions: Metastatic Prostate Adenocarcinoma

Interventions: Drug: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron

First Posted Date: 2020-12-28

Last Posted Date: 2022-09-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 16

Registration Number: NCT04685811

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Comparative Effectiveness of Telemedicine in Primary Care

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Congestive Heart Failure
Diabetes
Hypertension

Interventions: Other: Exposure to telemedicine, after the onset of the pandemic

First Posted Date: 2020-12-28

Last Posted Date: 2023-06-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 216000

Registration Number: NCT04684836

Locations: 🇺🇸
University of Florida, Gainesville, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Mount Sinai, New York, New York, United States

and more 1 locations

Virtual Reality for Pain Management in Burn Patients

Not Applicable

Recruiting

Conditions: Pain

Interventions: Other: Virtual Reality

First Posted Date: 2020-12-28

Last Posted Date: 2024-08-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 50

Registration Number: NCT04685486

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Richter Syndrome

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Hydroxydaunomycin

First Posted Date: 2020-12-22

Last Posted Date: 2024-10-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT04679012

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Mount Sinai- Icahn School of Medicine, New York, New York, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

Telehealth Language Intervention for Children With Autism Ages 2-4 Years

Not Applicable

Completed

Conditions: Autism Spectrum Disorder

Interventions: Behavioral: Toy Talk

First Posted Date: 2020-12-19

Last Posted Date: 2022-08-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 14

Registration Number: NCT04675580

Locations: 🇺🇸
Center for Autism and the Developing Brain/New York-Presbyterian Hospital, White Plains, New York, United States

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Pseudomonas Aeruginosa
Hematologic Malignancy
Pneumonia

Interventions: Drug: Ceftolozane / Tazobactam Injection

First Posted Date: 2020-12-17

Last Posted Date: 2024-08-09

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT04673175

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients

Not Applicable

Completed

Conditions: Ulcerative Colitis (UC)
Indeterminate Colitis
Crohn Disease (CD)

Interventions: Other: Vaccine Education

First Posted Date: 2020-12-17

Last Posted Date: 2023-07-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 200

Registration Number: NCT04672161

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Phase 2

Withdrawn

Conditions: Chronic Lymphocytic Leukemia
CLL/SLL

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-12-09

Last Posted Date: 2022-04-05

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT04660045

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2020-11-17

Last Posted Date: 2025-01-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 30

Registration Number: NCT04631744

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy